Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Mild to Moderate Alzheimer's Disease: early-phase trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Mild to Moderate Alzheimer's Disease: 2 US clinical trials tracked, none currently recruiting.
Mild to Moderate Alzheimer's Disease is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is GemVax & Kael, running 1 of these trials.
Enrollment posture brief
Registry condition mild-to-moderate-alzheimers-disease
OPEN 0 | RECR 0% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Mild to Moderate Alzheimer's Disease has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Mild to Moderate Alzheimer's Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Mild to Moderate Alzheimer's Disease is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)
GemVax & Kael
NCT05189210
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Cognition Therapeutics
NCT03507790
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Mild to Moderate Alzheimer's Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Mild to Moderate Alzheimer's Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Mild to Moderate Alzheimer's Disease page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Mild to Moderate Alzheimer's Disease trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- GemVax & Kael sponsors the most Mild to Moderate Alzheimer's Disease trials on record, review their full trial history before evaluating a specific study. See GemVax & Kael's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mild to Moderate Alzheimer's Disease condition card totals 2 registered trials; most-linked intervention GV1001 1.12mg; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.